1
|
Baltgalvis KA, Lamb KN, Symons KT, Wu CC, Hoffman MA, Snead AN, Song X, Glaza T, Kikuchi S, Green JC, Rogness DC, Lam B, Rodriguez-Aguirre ME, Woody DR, Eissler CL, Rodiles S, Negron SM, Bernard SM, Tran E, Pollock J, Tabatabaei A, Contreras V, Williams HN, Pastuszka MK, Sigler JJ, Pettazzoni P, Rudolph MG, Classen M, Brugger D, Claiborne C, Plancher JM, Cuartas I, Seoane J, Burgess LE, Abraham RT, Weinstein DS, Simon GM, Patricelli MP, Kinsella TM. Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase. Nature 2024; 629:435-442. [PMID: 38658751 DOI: 10.1038/s41586-024-07318-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2023] [Accepted: 03/14/2024] [Indexed: 04/26/2024]
Abstract
WRN helicase is a promising target for treatment of cancers with microsatellite instability (MSI) due to its essential role in resolving deleterious non-canonical DNA structures that accumulate in cells with faulty mismatch repair mechanisms1-5. Currently there are no approved drugs directly targeting human DNA or RNA helicases, in part owing to the challenging nature of developing potent and selective compounds to this class of proteins. Here we describe the chemoproteomics-enabled discovery of a clinical-stage, covalent allosteric inhibitor of WRN, VVD-133214. This compound selectively engages a cysteine (C727) located in a region of the helicase domain subject to interdomain movement during DNA unwinding. VVD-133214 binds WRN protein cooperatively with nucleotide and stabilizes compact conformations lacking the dynamic flexibility necessary for proper helicase function, resulting in widespread double-stranded DNA breaks, nuclear swelling and cell death in MSI-high (MSI-H), but not in microsatellite-stable, cells. The compound was well tolerated in mice and led to robust tumour regression in multiple MSI-H colorectal cancer cell lines and patient-derived xenograft models. Our work shows an allosteric approach for inhibition of WRN function that circumvents competition from an endogenous ATP cofactor in cancer cells, and designates VVD-133214 as a promising drug candidate for patients with MSI-H cancers.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | - Betty Lam
- Vividion Therapeutics, San Diego, CA, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | - Piergiorgio Pettazzoni
- Pharma Research and Early Development pRED F. Hoffmann-La Roche, Ltd, Basel, Switzerland
| | - Markus G Rudolph
- Pharma Research and Early Development pRED F. Hoffmann-La Roche, Ltd, Basel, Switzerland
| | - Moritz Classen
- Pharma Research and Early Development pRED F. Hoffmann-La Roche, Ltd, Basel, Switzerland
| | - Doris Brugger
- Pharma Research and Early Development pRED F. Hoffmann-La Roche, Ltd, Basel, Switzerland
| | - Christopher Claiborne
- Pharma Research and Early Development pRED F. Hoffmann-La Roche, Ltd, Basel, Switzerland
| | - Jean-Marc Plancher
- Pharma Research and Early Development pRED F. Hoffmann-La Roche, Ltd, Basel, Switzerland
| | - Isabel Cuartas
- Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain
| | - Joan Seoane
- Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain
| | | | - Robert T Abraham
- Vividion Therapeutics, San Diego, CA, USA
- Odyssey Therapeutics, San Diego, CA, USA
| | | | | | | | | |
Collapse
|
2
|
Xiao Z, Yang MG, Liu C, Sherwood T, Gilmore JL, Lin J, Li P, Wu DR, Tokarski J, Li S, Cheng L, Xie C, Fan J, Dierks E, Strnad J, Cvijic ME, Khan J, Ruzanov M, Galella M, Khandelwal P, Dyckman AJ, Mathur A, Lombardo LJ, Macor JE, Carter PH, Aranibar N, Burke JR, Weinstein DS. Structure-activity relationship study of central pyridine-derived TYK2 JH2 inhibitors: Optimization of the PK profile through C4' and C6 variations. Bioorg Med Chem Lett 2023; 91:129373. [PMID: 37315697 DOI: 10.1016/j.bmcl.2023.129373] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2023] [Revised: 05/22/2023] [Accepted: 06/07/2023] [Indexed: 06/16/2023]
Abstract
Efforts directed at improving potency and preparing structurally different TYK2 JH2 inhibitors from the first generation of compounds such as 1a led to the SAR study of new central pyridyl based analogs 2-4. The current SAR study resulted in the identification of 4h as a potent and selective TYK2 JH2 inhibitor with distinct structural differences from 1a. In this manuscript, the in vitro and in vivo profiles of 4h are described. The hWB IC50 of 4h was shown as 41 nM with 94% bioavailability in the mouse PK study.
Collapse
Affiliation(s)
- Zili Xiao
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States.
| | - Michael G Yang
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Chunjian Liu
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Trevor Sherwood
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - John L Gilmore
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - James Lin
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Peng Li
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Dauh-Rurng Wu
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - John Tokarski
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Sha Li
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Lihong Cheng
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Chunshan Xie
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Jingsong Fan
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Elizabeth Dierks
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Joann Strnad
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Mary Ellen Cvijic
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Javed Khan
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Max Ruzanov
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Michael Galella
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Purnima Khandelwal
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Alaric J Dyckman
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Arvind Mathur
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Louis J Lombardo
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - John E Macor
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Percy H Carter
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Nelly Aranibar
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - James R Burke
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - David S Weinstein
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| |
Collapse
|
3
|
Zhang X, Luukkonen LM, Eissler CL, Crowley VM, Yamashita Y, Schafroth MA, Kikuchi S, Weinstein DS, Symons KT, Nordin BE, Rodriguez JL, Wucherpfennig TG, Bauer LG, Dix MM, Stamos D, Kinsella TM, Simon GM, Baltgalvis KA, Cravatt BF. DCAF11 Supports Targeted Protein Degradation by Electrophilic Proteolysis-Targeting Chimeras. J Am Chem Soc 2021; 143:5141-5149. [PMID: 33783207 DOI: 10.1021/jacs.1c00990] [Citation(s) in RCA: 64] [Impact Index Per Article: 21.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Ligand-induced protein degradation has emerged as a compelling approach to promote the targeted elimination of proteins from cells by directing these proteins to the ubiquitin-proteasome machinery. So far, only a limited number of E3 ligases have been found to support ligand-induced protein degradation, reflecting a dearth of E3-binding compounds for proteolysis-targeting chimera (PROTAC) design. Here, we describe a functional screening strategy performed with a focused library of candidate electrophilic PROTACs to discover bifunctional compounds that degrade proteins in human cells by covalently engaging E3 ligases. Mechanistic studies revealed that the electrophilic PROTACs act through modifying specific cysteines in DCAF11, a poorly characterized E3 ligase substrate adaptor. We further show that DCAF11-directed electrophilic PROTACs can degrade multiple endogenous proteins, including FBKP12 and the androgen receptor, in human prostate cancer cells. Our findings designate DCAF11 as an E3 ligase capable of supporting ligand-induced protein degradation via electrophilic PROTACs.
Collapse
Affiliation(s)
- Xiaoyu Zhang
- The Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, California 92307, United States
| | - Lena M Luukkonen
- Vividion Therapeutics, 5820 Nancy Ridge Dr, San Diego, California 92121, United States
| | - Christie L Eissler
- Vividion Therapeutics, 5820 Nancy Ridge Dr, San Diego, California 92121, United States
| | - Vincent M Crowley
- The Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, California 92307, United States
| | - Yu Yamashita
- The Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, California 92307, United States.,Medicinal Chemistry Research Laboratories, New Drug Research Division, Otsuka Pharmaceutical Co., Ltd., 463-10 Kawauchi-cho, Tokushima, 771-0192, Japan
| | - Michael A Schafroth
- The Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, California 92307, United States
| | - Shota Kikuchi
- Vividion Therapeutics, 5820 Nancy Ridge Dr, San Diego, California 92121, United States
| | - David S Weinstein
- Vividion Therapeutics, 5820 Nancy Ridge Dr, San Diego, California 92121, United States
| | - Kent T Symons
- Vividion Therapeutics, 5820 Nancy Ridge Dr, San Diego, California 92121, United States
| | - Brian E Nordin
- Vividion Therapeutics, 5820 Nancy Ridge Dr, San Diego, California 92121, United States
| | - Joe L Rodriguez
- Vividion Therapeutics, 5820 Nancy Ridge Dr, San Diego, California 92121, United States
| | - Thomas G Wucherpfennig
- The Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, California 92307, United States
| | - Ludwig G Bauer
- The Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, California 92307, United States
| | - Melissa M Dix
- The Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, California 92307, United States
| | - Dean Stamos
- Vividion Therapeutics, 5820 Nancy Ridge Dr, San Diego, California 92121, United States
| | - Todd M Kinsella
- Vividion Therapeutics, 5820 Nancy Ridge Dr, San Diego, California 92121, United States
| | - Gabriel M Simon
- Vividion Therapeutics, 5820 Nancy Ridge Dr, San Diego, California 92121, United States
| | - Kristen A Baltgalvis
- Vividion Therapeutics, 5820 Nancy Ridge Dr, San Diego, California 92121, United States
| | - Benjamin F Cravatt
- The Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, California 92307, United States
| |
Collapse
|
4
|
Liu C, Lin J, Langevine C, Smith D, Li J, Tokarski JS, Khan J, Ruzanov M, Strnad J, Zupa-Fernandez A, Cheng L, Gillooly KM, Shuster D, Zhang Y, Thankappan A, McIntyre KW, Chaudhry C, Elzinga PA, Chiney M, Chimalakonda A, Lombardo LJ, Macor JE, Carter PH, Burke JR, Weinstein DS. Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2. J Med Chem 2020; 64:677-694. [PMID: 33370104 DOI: 10.1021/acs.jmedchem.0c01698] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
A search for structurally diversified Tyk2 JH2 ligands from 6 (BMS-986165), a pyridazine carboxamide-derived Tyk2 JH2 ligand as a clinical Tyk2 inhibitor currently in late development for the treatment of psoriasis, began with a survey of six-membered heteroaryl groups in place of the N-methyl triazolyl moiety in 6. The X-ray co-crystal structure of an early lead (12) revealed a potential new binding pocket. Exploration of the new pocket resulted in two frontrunners for a clinical candidate. The potential hydrogen bonding interaction with Thr599 in the pocket was achieved with a tertiary amide moiety, confirmed by the X-ray co-crystal structure of 29. When the diversity search was extended to nicotinamides, a single fluorine atom addition was found to significantly enhance the permeability, which directly led to the discovery of 7 (BMS-986202) as a clinical Tyk2 inhibitor that binds to Tyk2 JH2. The preclinical studies of 7, including efficacy studies in mouse models of IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus, will also be presented.
Collapse
Affiliation(s)
- Chunjian Liu
- Immunosciences Discovery Chemistry, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - James Lin
- Immunosciences Discovery Chemistry, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Charles Langevine
- Immunosciences Discovery Chemistry, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Daniel Smith
- Department of Discovery Synthesis, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Jianqing Li
- Department of Discovery Synthesis, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - John S Tokarski
- Molecular Structure and Design, Molecular Discovery Technologies, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Javed Khan
- Molecular Structure and Design, Molecular Discovery Technologies, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Max Ruzanov
- Molecular Structure and Design, Molecular Discovery Technologies, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Joann Strnad
- Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Adriana Zupa-Fernandez
- Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Lihong Cheng
- Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Kathleen M Gillooly
- Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - David Shuster
- Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Yifan Zhang
- Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Anil Thankappan
- Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Kim W McIntyre
- Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Charu Chaudhry
- Leads Discovery and Optimization, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Paul A Elzinga
- Metabolism and Pharmacokinetic Department, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Manoj Chiney
- Metabolism and Pharmacokinetic Department, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Anjaneya Chimalakonda
- Metabolism and Pharmacokinetic Department, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Louis J Lombardo
- Immunosciences Discovery Chemistry, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - John E Macor
- Immunosciences Discovery Chemistry, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Percy H Carter
- Immunosciences Discovery Chemistry, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - James R Burke
- Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - David S Weinstein
- Immunosciences Discovery Chemistry, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| |
Collapse
|
5
|
Burke JR, Cheng L, Gillooly KM, Strnad J, Zupa-Fernandez A, Catlett IM, Zhang Y, Heimrich EM, McIntyre KW, Cunningham MD, Carman JA, Zhou X, Banas D, Chaudhry C, Li S, D’Arienzo C, Chimalakonda A, Yang X, Xie JH, Pang J, Zhao Q, Rose SM, Huang J, Moslin RM, Wrobleski ST, Weinstein DS, Salter-Cid LM. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain. Sci Transl Med 2019; 11:11/502/eaaw1736. [DOI: 10.1126/scitranslmed.aaw1736] [Citation(s) in RCA: 76] [Impact Index Per Article: 15.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2018] [Revised: 02/24/2019] [Accepted: 07/03/2019] [Indexed: 12/30/2022]
Abstract
TYK2 is a nonreceptor tyrosine kinase involved in adaptive and innate immune responses. A deactivating coding variant has previously been shown to prevent receptor-stimulated activation of this kinase and provides high protection from several common autoimmune diseases but without immunodeficiency. An agent that recapitulates the phenotype of this deactivating coding variant may therefore represent an important advancement in the treatment of autoimmunity. BMS-986165 is a potent oral agent that similarly blocks receptor-stimulated activation of TYK2 allosterically and with high selectivity and potency afforded through optimized binding to a regulatory domain of the protein. Signaling and functional responses in human TH17, TH1, B cells, and myeloid cells integral to autoimmunity were blocked by BMS-986165, both in vitro and in vivo in a phase 1 clinical trial. BMS-986165 demonstrated robust efficacy, consistent with blockade of multiple autoimmune pathways, in murine models of lupus nephritis and inflammatory bowel disease, supporting its therapeutic potential for multiple immune-mediated diseases.
Collapse
|
6
|
Wrobleski ST, Moslin R, Lin S, Zhang Y, Spergel S, Kempson J, Tokarski JS, Strnad J, Zupa-Fernandez A, Cheng L, Shuster D, Gillooly K, Yang X, Heimrich E, McIntyre KW, Chaudhry C, Khan J, Ruzanov M, Tredup J, Mulligan D, Xie D, Sun H, Huang C, D’Arienzo C, Aranibar N, Chiney M, Chimalakonda A, Pitts WJ, Lombardo L, Carter PH, Burke JR, Weinstein DS. Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165. J Med Chem 2019; 62:8973-8995. [DOI: 10.1021/acs.jmedchem.9b00444] [Citation(s) in RCA: 105] [Impact Index Per Article: 21.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
|
7
|
Moslin R, Zhang Y, Wrobleski ST, Lin S, Mertzman M, Spergel S, Tokarski JS, Strnad J, Gillooly K, McIntyre KW, Zupa-Fernandez A, Cheng L, Sun H, Chaudhry C, Huang C, D'Arienzo C, Heimrich E, Yang X, Muckelbauer JK, Chang C, Tredup J, Mulligan D, Xie D, Aranibar N, Chiney M, Burke JR, Lombardo L, Carter PH, Weinstein DS. Identification of N-Methyl Nicotinamide and N-Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2). J Med Chem 2019; 62:8953-8972. [PMID: 31314518 DOI: 10.1021/acs.jmedchem.9b00443] [Citation(s) in RCA: 47] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
As a member of the Janus (JAK) family of nonreceptor tyrosine kinases, TYK2 plays an important role in mediating the signaling of pro-inflammatory cytokines including IL-12, IL-23, and type 1 interferons. The nicotinamide 4, identified by a SPA-based high-throughput screen targeting the TYK2 pseudokinase domain, potently inhibits IL-23 and IFNα signaling in cellular assays. The described work details the optimization of this poorly selective hit (4) to potent and selective molecules such as 47 and 48. The discoveries described herein were critical to the eventual identification of the clinical TYK2 JH2 inhibitor (see following report in this issue). Compound 48 provided robust inhibition in a mouse IL-12-induced IFNγ pharmacodynamic model as well as efficacy in an IL-23 and IL-12-dependent mouse colitis model. These results demonstrate the ability of TYK2 JH2 domain binders to provide a highly selective alternative to conventional TYK2 orthosteric inhibitors.
Collapse
|
8
|
Liu C, Lin J, Moslin R, Tokarski JS, Muckelbauer J, Chang C, Tredup J, Xie D, Park H, Li P, Wu DR, Strnad J, Zupa-Fernandez A, Cheng L, Chaudhry C, Chen J, Chen C, Sun H, Elzinga P, D’arienzo C, Gillooly K, Taylor TL, McIntyre KW, Salter-Cid L, Lombardo LJ, Carter PH, Aranibar N, Burke JR, Weinstein DS. Identification of Imidazo[1,2- b]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 Inhibitors. ACS Med Chem Lett 2019; 10:383-388. [PMID: 30891145 DOI: 10.1021/acsmedchemlett.9b00035] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2019] [Accepted: 02/21/2019] [Indexed: 01/12/2023] Open
Abstract
In sharp contrast to a previously reported series of 6-anilino imidazopyridazine based Tyk2 JH2 ligands, 6-((2-oxo-N1-substituted-1,2-dihydropyridin-3-yl)amino)imidazo[1,2-b]pyridazine analogs were found to display dramatically improved metabolic stability. The N1-substituent on 2-oxo-1,2-dihydropyridine ring can be a variety of alkyl, aryl, and heteroaryl groups, but among them, 2-pyridyl provided much enhanced Caco-2 permeability, attributed to its ability to form intramolecular hydrogen bonds. Further structure-activity relationship studies at the C3 position led to the identification of highly potent and selective Tyk2 JH2 inhibitor 6, which proved to be highly effective in inhibiting IFNγ production in a rat pharmacodynamics model and fully efficacious in a rat adjuvant arthritis model.
Collapse
Affiliation(s)
- Chunjian Liu
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - James Lin
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Ryan Moslin
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - John S. Tokarski
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Jodi Muckelbauer
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - ChiehYing Chang
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Jeffrey Tredup
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Dianlin Xie
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Hyunsoo Park
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Peng Li
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Dauh-Rurng Wu
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Joann Strnad
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Adriana Zupa-Fernandez
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Lihong Cheng
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Charu Chaudhry
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Jing Chen
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Cliff Chen
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Huadong Sun
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Paul Elzinga
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Celia D’arienzo
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Kathleen Gillooly
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Tracy L. Taylor
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Kim W. McIntyre
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Luisa Salter-Cid
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Louis J. Lombardo
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Percy H. Carter
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Nelly Aranibar
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - James R. Burke
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - David S. Weinstein
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| |
Collapse
|
9
|
Gong H, Weinstein DS, Lu Z, Duan JJW, Stachura S, Haque L, Karmakar A, Hemagiri H, Raut DK, Gupta AK, Khan J, Camac D, Sack JS, Pudzianowski A, Wu DR, Yarde M, Shen DR, Borowski V, Xie JH, Sun H, D'Arienzo C, Dabros M, Galella MA, Wang F, Weigelt CA, Zhao Q, Foster W, Somerville JE, Salter-Cid LM, Barrish JC, Carter PH, Dhar TGM. Identification of bicyclic hexafluoroisopropyl alcohol sulfonamides as retinoic acid receptor-related orphan receptor gamma (RORγ/RORc) inverse agonists. Employing structure-based drug design to improve pregnane X receptor (PXR) selectivity. Bioorg Med Chem Lett 2018; 28:85-93. [PMID: 29233651 DOI: 10.1016/j.bmcl.2017.12.006] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2017] [Revised: 11/18/2017] [Accepted: 12/04/2017] [Indexed: 02/04/2023]
Abstract
We disclose the optimization of a high throughput screening hit to yield benzothiazine and tetrahydroquinoline sulfonamides as potent RORγt inverse agonists. However, a majority of these compounds showed potent activity against pregnane X receptor (PXR) and modest activity against liver X receptor α (LXRα). Structure-based drug design (SBDD) led to the identification of benzothiazine and tetrahydroquinoline sulfonamide analogs which completely dialed out LXRα activity and were less potent at PXR. Pharmacodynamic (PD) data for compound 35 in an IL-23 induced IL-17 mouse model is discussed along with the implications of a high Ymax in the PXR assay for long term preclinical pharmacokinetic (PK) studies.
Collapse
Affiliation(s)
- Hua Gong
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - David S Weinstein
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Zhonghui Lu
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - James J-W Duan
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Sylwia Stachura
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Lauren Haque
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Ananta Karmakar
- Bristol-Myers Squibb-Biocon Research Center, Bangalore, India
| | | | | | | | - Javed Khan
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Dan Camac
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - John S Sack
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Andrew Pudzianowski
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Dauh-Rurng Wu
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Melissa Yarde
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Ding-Ren Shen
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Virna Borowski
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Jenny H Xie
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Huadong Sun
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Celia D'Arienzo
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Marta Dabros
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Michael A Galella
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Faye Wang
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Carolyn A Weigelt
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Qihong Zhao
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - William Foster
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - John E Somerville
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Luisa M Salter-Cid
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Joel C Barrish
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - Percy H Carter
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States
| | - T G Murali Dhar
- Bristol-Myers Squibb, Research and Development, Princeton, NJ 08543-4000, United States.
| |
Collapse
|
10
|
Moslin R, Gardner D, Santella J, Zhang Y, Duncia JV, Liu C, Lin J, Tokarski JS, Strnad J, Pedicord D, Chen J, Blat Y, Zupa-Fernandez A, Cheng L, Sun H, Chaudhry C, Huang C, D'Arienzo C, Sack JS, Muckelbauer JK, Chang C, Tredup J, Xie D, Aranibar N, Burke JR, Carter PH, Weinstein DS. Identification of imidazo[1,2- b]pyridazine TYK2 pseudokinase ligands as potent and selective allosteric inhibitors of TYK2 signalling. Medchemcomm 2017; 8:700-712. [PMID: 30108788 PMCID: PMC6071835 DOI: 10.1039/c6md00560h] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/10/2016] [Accepted: 12/06/2016] [Indexed: 12/19/2022]
Abstract
As a member of the Janus (JAK) family of non-receptor tyrosine kinases, TYK2 mediates the signaling of pro-inflammatory cytokines including IL-12, IL-23 and type 1 interferon (IFN), and therefore represents an attractive potential target for treating the various immuno-inflammatory diseases in which these cytokines have been shown to play a role. Following up on our previous report that ligands to the pseudokinase domain (JH2) of TYK2 suppress cytokine-mediated receptor activation of the catalytic (JH1) domain, the imidazo[1,2-b]pyridazine (IZP) 7 was identified as a promising hit compound. Through iterative modification of each of the substituents of the IZP scaffold, the cellular potency was improved while maintaining selectivity over the JH1 domain. These studies led to the discovery of the JH2-selective TYK2 inhibitor 29, which provided encouraging systemic exposures after oral dosing in mice. Phosphodiesterase 4 (PDE4) was identified as an off-target and potential liability of the IZP ligands, and selectivity for TYK2 JH2 over this enzyme was obtained by elaborating along selectivity vectors determined from analyses of X-ray co-crystal structures of representative ligands of the IZP class bound to both proteins.
Collapse
Affiliation(s)
- R Moslin
- Bristol-Myers Squibb Research , Princeton , New Jersey , USA .
| | - D Gardner
- Bristol-Myers Squibb Research , Princeton , New Jersey , USA .
| | - J Santella
- Bristol-Myers Squibb Research , Princeton , New Jersey , USA .
| | - Y Zhang
- Bristol-Myers Squibb Research , Princeton , New Jersey , USA .
| | - J V Duncia
- Bristol-Myers Squibb Research , Princeton , New Jersey , USA .
| | - C Liu
- Bristol-Myers Squibb Research , Princeton , New Jersey , USA .
| | - J Lin
- Bristol-Myers Squibb Research , Princeton , New Jersey , USA .
| | - J S Tokarski
- Bristol-Myers Squibb Research , Princeton , New Jersey , USA .
| | - J Strnad
- Bristol-Myers Squibb Research , Princeton , New Jersey , USA .
| | - D Pedicord
- Bristol-Myers Squibb Research , Princeton , New Jersey , USA .
| | - J Chen
- Bristol-Myers Squibb Research , Princeton , New Jersey , USA .
| | - Y Blat
- Bristol-Myers Squibb Research , Princeton , New Jersey , USA .
| | | | - L Cheng
- Bristol-Myers Squibb Research , Princeton , New Jersey , USA .
| | - H Sun
- Bristol-Myers Squibb Research , Princeton , New Jersey , USA .
| | - C Chaudhry
- Bristol-Myers Squibb Research , Princeton , New Jersey , USA .
| | - C Huang
- Bristol-Myers Squibb Research , Princeton , New Jersey , USA .
| | - C D'Arienzo
- Bristol-Myers Squibb Research , Princeton , New Jersey , USA .
| | - J S Sack
- Bristol-Myers Squibb Research , Princeton , New Jersey , USA .
| | - J K Muckelbauer
- Bristol-Myers Squibb Research , Princeton , New Jersey , USA .
| | - C Chang
- Bristol-Myers Squibb Research , Princeton , New Jersey , USA .
| | - J Tredup
- Bristol-Myers Squibb Research , Princeton , New Jersey , USA .
| | - D Xie
- Bristol-Myers Squibb Research , Princeton , New Jersey , USA .
| | - N Aranibar
- Bristol-Myers Squibb Research , Princeton , New Jersey , USA .
| | - J R Burke
- Bristol-Myers Squibb Research , Princeton , New Jersey , USA .
| | - P H Carter
- Bristol-Myers Squibb Research , Princeton , New Jersey , USA .
| | - D S Weinstein
- Bristol-Myers Squibb Research , Princeton , New Jersey , USA .
| |
Collapse
|
11
|
Conlon DA, Natalie KJ, Cuniere N, Razler TM, Zhu J, de Mas N, Tymonko S, Fraunhoffer KJ, Sortore E, Rosso VW, Xu Z, Adams ML, Patel A, Huang J, Gong H, Weinstein DS, Quiroz F, Chen DC. Development of a Practical Synthesis of Functionalized Azaxanthene-Derived Nonsteroidal Glucocorticoid Receptor Modulators. Org Process Res Dev 2016. [DOI: 10.1021/acs.oprd.6b00035] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | - Hua Gong
- Research
and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543-4000, United States
| | - David S. Weinstein
- Research
and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543-4000, United States
| | | | | |
Collapse
|
12
|
Yang MG, Dhar TGM, Xiao Z, Xiao HY, Duan JJW, Jiang B, Galella MA, Cunningham M, Wang J, Habte S, Shuster D, McIntyre KW, Carman J, Holloway DA, Somerville JE, Nadler SG, Salter-Cid L, Barrish JC, Weinstein DS. Improving the Pharmacokinetic and CYP Inhibition Profiles of Azaxanthene-Based Glucocorticoid Receptor Modulators—Identification of (S)-5-(2-(9-Fluoro-2-(4-(2-hydroxypropan-2-yl)phenyl)-5H-chromeno[2,3-b]pyridin-5-yl)-2-methylpropanamido)-N-(tetrahydro-2H-pyran-4-yl)-1,3,4-thiadiazole-2-carboxamide (BMS-341). J Med Chem 2015; 58:4278-90. [DOI: 10.1021/acs.jmedchem.5b00257] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- Michael G. Yang
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - T. G. Murali Dhar
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Zili Xiao
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Hai-Yun Xiao
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - James J.-W. Duan
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Bin Jiang
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Michael A. Galella
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Mark Cunningham
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Jinhong Wang
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Sium Habte
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - David Shuster
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Kim W. McIntyre
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Julie Carman
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Deborah A. Holloway
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - John E. Somerville
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Steven G. Nadler
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Luisa Salter-Cid
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Joel C. Barrish
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - David S. Weinstein
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| |
Collapse
|
13
|
Tokarski JS, Zupa-Fernandez A, Tredup JA, Pike K, Chang C, Xie D, Cheng L, Pedicord D, Muckelbauer J, Johnson SR, Wu S, Edavettal SC, Hong Y, Witmer MR, Elkin LL, Blat Y, Pitts WJ, Weinstein DS, Burke JR. Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain. J Biol Chem 2015; 290:11061-74. [PMID: 25762719 DOI: 10.1074/jbc.m114.619502] [Citation(s) in RCA: 63] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2014] [Indexed: 01/04/2023] Open
Abstract
Inhibition of signal transduction downstream of the IL-23 receptor represents an intriguing approach to the treatment of autoimmunity. Using a chemogenomics approach marrying kinome-wide inhibitory profiles of a compound library with the cellular activity against an IL-23-stimulated transcriptional response in T lymphocytes, a class of inhibitors was identified that bind to and stabilize the pseudokinase domain of the Janus kinase tyrosine kinase 2 (Tyk2), resulting in blockade of receptor-mediated activation of the adjacent catalytic domain. These Tyk2 pseudokinase domain stabilizers were also shown to inhibit Tyk2-dependent signaling through the Type I interferon receptor but not Tyk2-independent signaling and transcriptional cellular assays, including stimulation through the receptors for IL-2 (JAK1- and JAK3-dependent) and thrombopoietin (JAK2-dependent), demonstrating the high functional selectivity of this approach. A crystal structure of the pseudokinase domain liganded with a representative example showed the compound bound to a site analogous to the ATP-binding site in catalytic kinases with features consistent with high ligand selectivity. The results support a model where the pseudokinase domain regulates activation of the catalytic domain by forming receptor-regulated inhibitory interactions. Tyk2 pseudokinase stabilizers, therefore, represent a novel approach to the design of potent and selective agents for the treatment of autoimmunity.
Collapse
Affiliation(s)
| | | | | | - Kristen Pike
- the Department of Leads Discovery and Optimization, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut 06492
| | | | | | | | | | | | | | | | | | - Yang Hong
- Discovery Chemistry, Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543 and
| | | | - Lisa L Elkin
- the Department of Leads Discovery and Optimization, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut 06492
| | | | - William J Pitts
- Discovery Chemistry, Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543 and
| | - David S Weinstein
- Discovery Chemistry, Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543 and
| | | |
Collapse
|
14
|
Gong H, Yang M, Xiao Z, Doweyko AM, Cunningham M, Wang J, Habte S, Holloway D, Burke C, Shuster D, Gao L, Carman J, Somerville JE, Nadler SG, Salter-Cid L, Barrish JC, Weinstein DS. Discovery of acylurea isosteres of 2-acylaminothiadiazole in the azaxanthene series of glucocorticoid receptor agonists. Bioorg Med Chem Lett 2014; 24:3268-73. [DOI: 10.1016/j.bmcl.2014.06.010] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2014] [Revised: 06/03/2014] [Accepted: 06/05/2014] [Indexed: 01/27/2023]
|
15
|
Weinstein DS, Gong H, Doweyko AM, Cunningham M, Habte S, Wang JH, Holloway DA, Burke C, Gao L, Guarino V, Carman J, Somerville JE, Shuster D, Salter-Cid L, Dodd JH, Nadler SG, Barrish JC. Azaxanthene Based Selective Glucocorticoid Receptor Modulators: Design, Synthesis, and Pharmacological Evaluation of (S)-4-(5-(1-((1,3,4-Thiadiazol-2-yl)amino)-2-methyl-1-oxopropan-2-yl)-5H-chromeno[2,3-b]pyridin-2-yl)-2-fluoro-N,N-dimethylbenzamide (BMS-776532) and Its Methylene Homologue (BMS-791826). J Med Chem 2011; 54:7318-33. [DOI: 10.1021/jm200879j] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Affiliation(s)
- David S. Weinstein
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Hua Gong
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Arthur M. Doweyko
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Mark Cunningham
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Sium Habte
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Jin Hong Wang
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Deborah A. Holloway
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Christine Burke
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Ling Gao
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Victor Guarino
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Julie Carman
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - John E. Somerville
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - David Shuster
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Luisa Salter-Cid
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - John H. Dodd
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Steven G. Nadler
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| | - Joel C. Barrish
- Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
| |
Collapse
|
16
|
Yang BV, Weinstein DS, Doweyko LM, Gong H, Vaccaro W, Huynh T, Xiao HY, Doweyko AM, McKay L, Holloway DA, Somerville JE, Habte S, Cunningham M, McMahon M, Townsend R, Shuster D, Dodd JH, Nadler SG, Barrish JC. Dimethyl-diphenyl-propanamide derivatives as nonsteroidal dissociated glucocorticoid receptor agonists. J Med Chem 2010; 53:8241-51. [PMID: 21073190 DOI: 10.1021/jm100957a] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
A series of 2,2-dimethyl-3,3-diphenyl-propanamides as novel glucocorticoid receptor modulators is reported. SAR exploration led to the identification of 4-hydroxyphenyl propanamide derivatives displaying good agonist activity in GR-mediated transrepression assays and reduced agonist activity in GR-mediated transactivation assays. Compounds 17 and 30 showed anti-inflammatory activity comparable to prednisolone in the rat carrageenan-induced paw edema model, with markedly decreased side effects with regard to increases in blood glucose and expression of hepatic tyrosine aminotransferase. A hypothetical binding mode accounting for the induction of the functional activity by a 4-hydroxyl group is proposed.
Collapse
Affiliation(s)
- Bingwei V Yang
- Bristol-Myers Squibb Company, Research and Development, Princeton, New Jersey 08543-4000, United States
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
|
18
|
Valdés-Dapena MA, Weinstein DS. The parathyroids in sudden, unexpected death in infants. Acta Pathol Microbiol Scand A 2009; 79:228-32. [PMID: 5574604 DOI: 10.1111/j.1699-0463.1971.tb01813.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|
19
|
Yang BV, Vaccaro W, Doweyko AM, Doweyko LM, Huynh T, Tortolani D, Nadler SG, McKay L, Somerville J, Holloway DA, Habte S, Weinstein DS, Barrish JC. Discovery of novel dihydro-9,10-ethano-anthracene carboxamides as glucocorticoid receptor modulators. Bioorg Med Chem Lett 2009; 19:2139-43. [DOI: 10.1016/j.bmcl.2009.03.006] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2009] [Accepted: 03/03/2009] [Indexed: 11/25/2022]
|
20
|
Weinstein DS, Liu W, Ngu K, Langevine C, Combs DW, Zhuang S, Chen C, Madsen CS, Harper TW, Robl JA. Discovery of selective imidazole-based inhibitors of mammalian 15-lipoxygenase: highly potent against human enzyme within a cellular environment. Bioorg Med Chem Lett 2007; 17:5115-20. [PMID: 17656086 DOI: 10.1016/j.bmcl.2007.07.011] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2007] [Revised: 07/02/2007] [Accepted: 07/05/2007] [Indexed: 01/18/2023]
Abstract
A series of 2,4,5-tri-substituted imidazoles has proven to be highly potent in inhibiting mammalian 15-lipoxygenase (15-LO) with excellent selectivity over human isozymes 5- and P-12-LO. Non-symmetrical sulfamides (e.g., 21a-n) were found to be suitable replacements for the earlier arylsulfonamide-containing members of this series (e.g., 2, 14a-p). Several members of these series also demonstrated potent inhibition of human 15-LO in a cell-based assay.
Collapse
Affiliation(s)
- David S Weinstein
- Department of Discovery Chemistry, Bristol-Myers Squibb, Research and Development, PO Box 4000, Princeton, NJ 08543-5400, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Weinstein DS, Liu W, Gu Z, Langevine C, Ngu K, Fadnis L, Combs DW, Sitkoff D, Ahmad S, Zhuang S, Chen X, Wang FL, Loughney DA, Atwal KS, Zahler R, Macor JE, Madsen CS, Murugesan N. Tryptamine and homotryptamine-based sulfonamides as potent and selective inhibitors of 15-lipoxygenase. Bioorg Med Chem Lett 2005; 15:1435-40. [PMID: 15713402 DOI: 10.1016/j.bmcl.2004.12.081] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2004] [Revised: 12/23/2004] [Accepted: 12/30/2004] [Indexed: 11/30/2022]
Abstract
A series of inhibitors of mammalian 15-lipoxygenase based on tryptamine and homotryptamine scaffolds is described. Compounds with aryl substituents at C-2 of the indole core of tryptamine and homotryptamine sulfonamides (e.g., 37a-p) proved to be potent inhibitors of the isolated enzyme. Selected compounds also demonstrated desirable inhibition selectivities over isozymes 5- and P-12-LO.
Collapse
Affiliation(s)
- David S Weinstein
- Bristol-Myers Squibb Pharmaceutical Research Institute, Bristol-Myers Squibb, PO Box 4000, Princeton, NJ 08543, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Ahmad S, Ngu K, Combs DW, Wu SC, Weinstein DS, Liu W, Chen BC, Chandrasena G, Dorso CR, Kirby M, Atwal KS. Aminoimidazoles as bioisosteres of acylguanidines: novel, potent, selective and orally bioavailable inhibitors of the sodium hydrogen exchanger isoform-1. Bioorg Med Chem Lett 2004; 14:177-80. [PMID: 14684323 DOI: 10.1016/j.bmcl.2003.09.066] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
Inhibition of the sodium hydrogen exchanger isoform-1 (NHE-1) has been shown to limit damage to the myocardium under ischemic conditions in animals. While most known NHE-1 inhibitors are acylguanidines, this report describes the design and synthesis of a series of heterocyclic inhibitors of NHE-1 including aminoimidazoles with undiminished in vitro activity and oral bioavailability.
Collapse
Affiliation(s)
- Saleem Ahmad
- Bristol-Myers Squibb Pharmaceutical Research Institute, PO Box 4000, Princeton, NJ 08543, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Weinstein DS. Pulmonary sarcoidosis: calcified micronodular pattern simulating pulmonary alveolar microlithiasis. J Thorac Imaging 1999; 14:218-20. [PMID: 10404510] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
Abstract
A case of sarcoidosis demonstrating an unusual pattern of profuse micronodular calcification is presented. The striking similarity with the so-called pathognomonic appearance of pulmonary alveolar microlithiasis and the progressive deterioration of pulmonary function are emphasized.
Collapse
Affiliation(s)
- D S Weinstein
- Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia 19104, USA
| |
Collapse
|
24
|
Weinstein DS, Nicolaou KC. Synthesis of the namenamicin A–C disaccharide: towards the total synthesis of namenamicin. ACTA ACUST UNITED AC 1999. [DOI: 10.1039/a809697j] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
25
|
Weinstein DS, Skipper A. Determining competence in estimating energy needs. J Am Diet Assoc 1998; 98:129-30; author reply 130. [PMID: 12515409 DOI: 10.1016/s0002-8223(98)00032-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
26
|
Weinstein DS, Furman J. Enteral formulas. Nurs Clin North Am 1997; 32:669-83. [PMID: 9386218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
This article is intended to assist the nurse in caring for the patient who requires medical nutritional formulas, either as a complete diet or as a dietary supplement, to increase the nurse's knowledge of formula components, when and why different formulas are used, and when a change in formula may be indicated. Common formulas are broadly categorized throughout the article based on the form of the protein.
Collapse
Affiliation(s)
- D S Weinstein
- Nutrition Consultation Service, Rush Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612, USA
| | | |
Collapse
|
27
|
Abstract
BACKGROUND Triple-helical nucleic acids, first reported in the late 1950s, are receiving attention for their possible involvement in controlling gene expression. Certain sequences of DNA are believed to form local triple-helical structures (H-form DNA), although this has not been directly observed in vivo. Studies carried out in our laboratories have suggested that self-replicating oligonucleotides could have been involved in chemical evolution via triple-helical intermediates. In addition to self-replication mechanisms, elucidating processes for the nonenzymatic elongation of biologically relevant polymers remains an important challenge in understanding the origin of life. To this end, we have studied a novel ligation of oligodeoxyribonucleotides that lie within a triple helix. RESULTS The chemical end-ligation of homopyrimidine oligodeoxyribonucleotides on a triple helix is reported. This selective process, induced by cyanoimidazole, is facilitated by a template effect of the DNA aggregate and occurs between the 3' end (hydroxyl) of the third minor-groove-bound strand and the 5' end (phosphate) of the antiparallel oligopyrimidine strand. CONCLUSIONS Double-helical homopurine/homopyrimidine DNA can serve as a template for the elongation of oligonucleotides in a manner that has not been described previously. The end-ligation of homopyrimidine oligomers, a nonenzymatic process, proceeds via a requisite triple-helical intermediate and constitutes an efficient and selective method for the template-directed elongation of nucleic acids. Such a process could conceivably have been involved in the elongation of primordial information-bearing biopolymers.
Collapse
Affiliation(s)
- T Li
- Department of Chemistry The Skaggs Institute for Chemical Biology The Scripps Research Institute 10550 North Torrey Pines Road, La Jolla, California 92037, USA
| | | | | |
Collapse
|
28
|
Steinfeld AD, Weinstein DS. Lymphangiographic detection of scalene node metastases from cervical carcinoma. AJR Am J Roentgenol 1978; 130:371-2. [PMID: 414599 DOI: 10.2214/ajr.130.2.371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|